A fully customized commercial supply solution, exclusive for your product or portfolio


Our innovative, high-responsive supply solution Ibex® Dedicate allows you to delay your capacity build decisions and better manage investment risk. A pre-built wing and faster ramp-up save you up to 30 months total time to market. Flexible ownership and operating models give you freedom of choice, in combination with a technology-agnostic solution that can be tailored to suit mammalian and microbial production, vaccines, and cell and gene therapy.

Faster time-to-market. Full build-out flexibility. Significant reduction in investment risk. Tailored business and ownership models.
  • In house manufacturing or outsourcing, what if none of those models fit?


    As the biopharmaceutical market evolves, new forms of manufacturing partnerships are required beyond the typical in-house or outsource models. Timelines are shorter, regulatory guidelines are changing, and strategies for market entry become more diverse. How do you best secure capacity if you launch with one indication, but have clinical trials for two more in the pipeline?

    A successful internal build relies on a business case designed to meet the forecasted demand within the company. This is a challenging exercise, as uncertainty is high and situations with underutilized facilities or out of stock product need to be avoided at all cost. Also, there is the time factor. An internal build may take 4-5 years and in addition to that comes the ramp up time before you reach full capacity.

    The traditional CDMO model can be a faster, attractive option. However, what if your company prefers ownership and increased control? What if your pipeline looks promising or your molecule becomes the next blockbuster? In those situations, does your CDMO have enough capacity and flexibility to accommodate your current and future needs?

    Where the traditional business models do not fit perfectly – the best solution often lies in innovation. If neither in-house, nor outsource fits – then look for an option that combines the best of both worlds.

  • Answer:

    A breakthrough or fast track approval of a new drug should be cause for celebration. However, bright times can quickly turn gloomy. If market demand is much greater than you expect, you’ll have trouble producing enough, which puts you at risk of stock-outs. Competitors can overtake you and you could lose market share or see your stock price fall but more importantly life changing drugs could fail reaching patients. If your product uptake is much slower than you had anticipated, then you will be paying for underutilized capacity with high production costs or cancellation fees.

    What is needed to get this right, is the agility to change course from production commitment without slowing down or wasting money. If you have access to a flexible and tailored supply solution including a facility design that can rapidly scale up with your needs, demand volatility will not be an issue.

  • Answer:

    Pipeline growth in pharma frequently comes from small companies. While historically, the objective of these companies was to quickly partner with a big player, ambitious biotechs are now looking to keep their molecules longer and sometimes all the way to commercialization.

    A successful commercialization requires knowledge about how to successfully implement CMC strategies, an area where small companies typically have limited resources and expertise. Hence, they will most likely rely on a CDMO under a traditional outsourcing model. But does it always have to be that way?

    Not necessarily. Partnering with an experienced CDMO can help realizing the dream of building tailored capacity for the molecule in question and to eventually own it.

    It is probably too much to ask for a small, innovative company to excel in manufacturing. However, finding an experienced CDMO partner can bridge the gaps that a small company has, to be able to take the candidate through clinical trials to the market and beyond.